- Home
- LGI vs AMRN Comparison
LGI vs AMRN Comparison
Compare LGI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | AMRN |
|---|---|---|
| Founded | 2004 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.7M | 287.9M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | LGI | AMRN |
|---|---|---|
| Price | $17.26 | $13.61 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 30.1K | ★ 74.3K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $15.32 | $12.96 |
| 52 Week High | $19.88 | $20.90 |
Technical Indicators
Market Signals| Indicator | LGI | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | N/A |
| Support Level | $17.27 | N/A |
| Resistance Level | $17.92 | N/A |
| Average True Range (ATR) | 0.32 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 25.91 | 0.00 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.